Publication:

Assessment of safety and effectiveness of desoximetasone emollient cream 0.25% in comparison to mometasone cream 0.1% in Indian patients with eczema

Background Topical corticosteroids have become indispensable in the treatment of eczema. The current study was conducted to assess the safety and effectiveness of Desoximetasone emollient cream 0.25% (DESO) compared to Mometasone cream 0.1% (MOM) in patients with eczema.

Methods This was a prospective, observational, open label, multicentre post marketing study at real-life scenario. Newly diagnosed, treatment naïve patients with clinical diagnosis of eczema were enrolled. All patients received either DESO or MOM for 3 weeks. Primary end point was proportion of patients developing adverse events. Secondary endpoints comprised of change in visual analog scale for perception of improvement in intensity of pruritus at day 14 and day 21 from baseline, change in eczema area and severity index (EASI) score at day 0 and day 21.

Results 45 patients in DESO group and 43 patients in MOM group completed study. DESO and MOM were well tolerated. Severity of pruritus was significantly reduced in 54.59% patients in DESO group compared to 45.60% patients in MOM group on day 14 (p=0.023). Severity of pruritus was reduced in 69.16% patients in DESO group as compared to 66.97 % patients in MOM group on day 21 (p=NS). There was a statistically significant reduction (p<0.001) in EASI score at day 21 and as compared to baseline within the study groups, but without any difference between the groups.

Conclusions Desoximetasone 0.25% emollient cream was well tolerated in the treatment of eczema with earlier reduction in pruritus as compared to Mometasone furoate 1% cream.